0
Back To Top Jump Location
Sign In  | Cart
Journals | Topic Collections | CME | Guidelines | Subscribe
Left Shadow
Right Shadow
HEART Group | May 2008

A Statement on Ethics From the HEART Group FREE

[+] Author Information

American College of Cardiology Foundation

J Am Coll Cardiol Img. 2008;1(3):410-412. doi:10.1016/j.jcmg.2008.02.001
Published online
Article
text A A A

Over the past several years, the editors of leading international cardiovascular journals have met to form the HEART group and to discuss areas of growing, common interest. Recently, the HEART group has developed a document that addresses general ethical principles in the conduct of the scientific process with which all of the editors concur. Published essentially simultaneously in all of the participating journals, including this journal, this document presents the ethical tenets accepted by all of the undersigned editors that will (continue to) guide their decisions in the editorial process.

These are the general principles on which the HEART Group is based and by which we, as a group, abide; however, please note that individual journal members and their respective societies may have their own rules and regulations that supersede the guidelines of the HEART Group.

Hugo Ector, MD, PhD

Editor-in-Chief

Patrizio Lancellotti, MD

Editor-in-Chief

William C. Roberts, MD

Editor-in-Chief

Nanette K. Wenger, MD

Editor-in-Chief

Arthur J. Moss, MD

Editor-in-Chief

Eldon R. Smith, MD

Editor-in-Chief

Jeffrey S. Borer, MD

Editor-in-Chief

Kim A. Eagle, MD

Editor-in-Chief

Jane Freedman, MD

Incoming Editor-in-Chief

Henry Krum, PhD

Incoming Editor-in-Chief

Chim Lang, MD

Incoming Editor-in-Chief

Willem J. Remme, MD, PhD

Editor-in-Chief

Hans Michael Piper, MD, PhD

Editor-in-Chief

Christopher J. White, MD

Editor-in-Chief

Joseph Loscalzo, MD, PhD

Editor-in-Chief

Eduardo Marbán, MD, PhD

Editor-in-Chief

Burton E. Sobel, MD

Editor

Robert Roberts, MD

Editor

Shahbudin H. Rahimtoola, MD

Editor

A. John Camm, MD

Editor-in-Chief

Frans Van de Werf, MD

Editor-in-Chief

Karl Swedberg, MD, PhD

Editor-in-Chief

Adam D. Timmis, MD

Editor

Kathleen S. Stone, PhD, RN

Editor-in-Chief

Douglas P. Zipes, MD

Editor-in-Chief

David G. Iosseliani, MD

Editor-in-Chief

Allen J. Taylor, MD

Editor-in-Chief

Michael R. Rosen, MD

Editor

Cindy L. Grines, MD

Editor-in-Chief

Anthony N. DeMaria, MD

Editor-in-Chief

Jagat Narula, MD, PhD

Editor-in-Chief

Spencer B. King III, MD

Editor-in-Chief

Galen S. Wagner, MD

Editor-in-Chief

Sanjeev Saksena, MD

Editor-in-Chief

Alan S. Pearlman, MD

Editor-in-Chief

Endre Bodnar, MD, PhD

Editor-in-Chief

Robert W. Emery, MD

Incoming Editor-in-Chief

Lawrence H. Cohn, MD

Editor-in-Chief

Ernst E. van der Wall, MD

Editor-in-Chief

Ra-id Abdulla, MD

Editor-in-Chief

Michael Lesch, MD

Editor

Fernando Alfonso, MD, PhD

Editor-in-Chief

Rolf Ekroth, MD

Chief Editor

The purpose of this is to ensure transparency and honesty in the scientific process that promotes ethical conduct in the performance and publication of research.

The following will be considered as parts of this process:

  • a. Disclosure of potential conflicts of interest for all involved in the performance of research and in the evaluation and publication process of a manuscript. Relevant relationships with commercial interests will be defined in terms of levels and nature of support. The nature of support will be listed as grants, supplies/equipment, type of employment, or personal income. Equity and royalty interests should be stated as well as any fiduciary relationship with the sponsor.

  • b. Establish thorough review processes particularly alert to discovering scientific fraud and data falsification, redundant or duplicate publication, and plagiarism, and to adopt a uniform standard of dealing with authors guilty of fraudulent practices.

  • c. Maintain confidentiality and embargos where appropriate.

  • d. Create uniform criteria to establish authorship. To qualify for authorship, individuals must have made substantial contributions to the intellectual content of the paper in at least 1 of the following areas: conceived and designed the research; acquired the data; analyzed and interpreted the data; performed statistical analysis; handled funding and supervision; drafted the manuscript; or made critical revision of the manuscript for important intellectual content.

  • Authors must give final approval of the version to be submitted and any revised version to be published. For multicenter trials, individuals who accept direct responsibility for the manuscript should fully meet the criteria for authorship previously defined; contributors not meeting these criteria should be acknowledged.

  • e. Note avoidance of false claims of ownership and priority, by attention to previous publications.

  • f. Establish avoidance of excessive claims of benefits of a product/technique in the publication as well as with news media.

  • g. Note compliance with institutional review board requirements and, when appropriate, approved laboratory procedures for animal research, and that the research conforms to the ethical standards of the Declaration of Helsinki, the Geneva Declaration, the Belmont Report, and Good Clinical Practices from the FDA, and the submission conforms to the International Committee of Medical Journal Editors (ICMJE) “Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication” (www.ICMJE.org).

Figures

Tables

Interactive Graphics

Video

References

Correspondence

Submit a Letter

Latest JACC CME

Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.

April 2013- JACC CME Activity
Repeat Revascularization and Outcome

March 2013- JACC CME Activity
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

Feb 2013- JACC CME Activity
Results from the BARI 2D Trial

Jan 2013- JACC CME Activity
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Dec 2012- JACC CME Activity
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

Nov 2012- JACC CME Activity
A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials

Oct 2012- JACC CME Activity
Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders

Sept 2012- JACC CME Activity
Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Aug 2012- JACC CME Activity
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

July 2012- JACC CME Activity
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction

For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.

 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.
Submit a Comment
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
LV Mass Assessed by Echocardiography and CMR, Cardiovascular Outcomes, and Medical Practice
J Am Coll Cardiol Img. 2012;5(8):837-848. doi:10.1016/j.jcmg.2012.06.003.
LV Segmentation and Mechanics in HCM: Twisting the Rubik's Cube Into Perfection!
J Am Coll Cardiol Img. 2012;5(7):765-768. doi:10.1016/j.jcmg.2012.05.009.
Related Topics
PubMed Articles
The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation.
Am Heart J. 2009;157(3):423-7.
Advances in cell-based therapy for structural heart disease.
Prog Cardiovasc Dis. 2007 May-Jun;49(6):387-95.
Left Shadow
Right Shadow
logo © 2013 American College of Cardiology Foundation
Powered bySilverchair Information Systems